Biology Reference
In-Depth Information
233. Foray N, Marot D, Randrianarison V, et al. Constitutive associa-
tion of BRCA1 and c-Abl and its ATM-dependent disruption after
irradiation. Mol Cell Biol 2002;
22
:4020
239. Kaelin Jr WG. The concept of synthetic lethality in the context of
anticancer therapy. Nat Rev Cancer 2005;
5
:689
98.
240. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose)
polymerase in tumors from BRCA mutation carriers. N Engl J
Med 2009;
361
:123
e
32.
234. Mantovani F, Piazza S, Gostissa M, et al. Pin1 links the activities
of c-Abl and p300 in regulating p73 function. Mol Cell
2004;
14
:625
e
34.
241. Martin SA, McCarthy A, Barber LJ, et al. Methotrexate induces
oxidative DNA damage and is selectively lethal to tumour cells
with defects in the DNA mismatch repair gene MSH2. EMBO Mol
Med 2009;
1
:323
e
36.
235. Sphyris N, Morris RG, Harrison DJ. Induction of p21 and nuclear
accumulation of TAp73alpha and c-abl during apoptosis of
cisplatin-treated primary pancreatic acinar cells.
e
Int
J Oncol
37.
242. Martin SA, McCabe N, Mullarkey M, et al. DNA polymerases as
potential therapeutic targets for cancers deficient in the DNA
mismatch repair proteins MSH2 or MLH1. Cancer Cell
2010;
17
:235
e
70.
236. Wang Q, Zhang H, Guerrette S, et al. Adenosine nucleotide
modulates the physical interaction between hMSH2 and BRCA1.
Oncogene 2001;
20
:4640
2004;
25
:1661
e
9.
237. Roos WP, Nikolova T, Quiros S, et al. Brca2/Xrcc2 dependent HR,
but not NHEJ, is required for protection against O(6)-
methylguanine triggered apoptosis, DSBs and chromosomal
aberrations by a process leading to SCEs. DNA Repair (Amst)
2009;
8
:72
e
48.
243. Vilar E, Mukherjee B, Kuick R, et al. Gene expression patterns in
mismatch repair-deficient colorectal cancers highlight the
potential therapeutic role of inhibitors of the phosphatidylinositol
3-kinase-AKT-mammalian target of rapamycin pathway. Clin
Cancer Res 2009;
15
:2829
e
86.
238. Smith SS, Kaplan BE, Sowers LC, Newman EM. Mechanism of
human methyl-directed DNA methyltransferase and the fidelity
of cytosine methylation. Proc Natl Acad Sci, USA 1992;
89
:4744
e
39.
244. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation
predicts sensitivity to MEK inhibition. Nature 2006;
439
:358
e
e
8.
e
62.
